E2 ModeratePreliminaryPEM not requiredObservationalPeer-reviewedMachine draft
General theory of inflammation: patient self-administration of hydrocortisone safely achieves superior control of hydrocortisone-responding disorders by matching dosage with symptom intensity.
Irwin, John B, Baldwin, A L, Stenberg, Virgil I · Journal of inflammation research · 2019 · DOI
Quick Summary
This study tested whether people with various chronic inflammatory conditions, including ME/CFS, could safely manage their own low-dose hydrocortisone treatment by adjusting it based on symptom flares. Over 2,000 participants achieved an average 76% improvement in symptoms while taking about 12 mg of hydrocortisone daily, and no serious side effects were reported.
Why It Matters
ME/CFS is included in this multi-condition analysis examining inflammation-based treatment. If validated, patient-directed low-dose hydrocortisone might offer a non-pharmacist-dependent management strategy for ME/CFS patients experiencing inflammatory symptom flares, particularly during periods of stress or infection.
Observed Findings
- 2,015 of 2,428 enrolled participants completed the 24-week protocol (83% completion rate)
- Average composite symptom improvement across all disorders was 76%
- Participants averaged 12 mg/day hydrocortisone ingestion during maintenance
- No significant adverse reactions were reported in the study cohort
- 25 ME/CFS patients were enrolled, though individual outcomes for this subgroup were not separately reported
Inferred Conclusions
- Patient self-administration of low-dose hydrocortisone can safely achieve symptom control across multiple chronic inflammatory conditions
- Chronic inflammation may be a unifying pathophysiological mechanism across diverse conditions with different symptom presentations depending on affected body systems
- Stressor minimization combined with targeted hydrocortisone dosing may reduce overall corticosteroid consumption and participant discomfort
Remaining Questions
- What were the specific outcomes and response rates for the 25 ME/CFS participants separately from the larger cohort?
- How does patient self-titration of hydrocortisone perform compared to fixed-dose or physician-managed approaches in controlled trials?
What This Study Does Not Prove
This study does not prove that hydrocortisone is safe or effective specifically for ME/CFS; the 25 ME/CFS participants were analyzed together with 1,990 others with different disorders, obscuring condition-specific outcomes. The open-label design and absence of a control group prevent determining whether improvements resulted from hydrocortisone, placebo effect, stressor reduction, natural history, or study participation itself. Long-term safety of repeated low-dose hydrocortisone use remains unclear.
Tags
Symptom:PainFatigue
Method Flag:Weak Case DefinitionNo ControlsMixed Cohort
Metadata
- DOI
- 10.2147/JIR.S195165
- PMID
- 31354330
- Review status
- Machine draft
- Evidence level
- Single-study or moderate support from human research
- Last updated
- 8 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →